Annovis Announces Closing of $6 Million Registered Direct Offering of Common Stock

Rhea-AI Summary

Annovis (NYSE: ANVS) closed a registered direct offering on October 15, 2025 selling an aggregate of 4,000,000 shares (or pre-funded warrants) at $1.50 per share, generating approximately $6.0 million in gross proceeds before placement agent fees and offering expenses. H.C. Wainwright & Co. served as exclusive placement agent. The company intends to use net proceeds for working capital and general corporate purposes. The securities were offered under a Form S-3 shelf registration (No. 333-276814) declared effective Feb 12, 2024, and via a prospectus supplement filed with the SEC.

Positive

• Gross proceeds of approximately $6.0 million
• Net proceeds allocated to working capital and general corporate purposes

Negative

• Issued 4,000,000 shares (or pre-funded warrants) at $1.50, diluting shareholders
• Gross proceeds stated before placement agent fees and offering expenses

MALVERN, Pa., Oct. 15, 2025 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative diseases such as Alzheimer’s disease (AD) and Parkinson’s disease (PD), today announced the closing of its previously announced registered direct offering for the purchase of an aggregate of 4,000,000 shares of its common stock (or pre-funded warrants in lieu thereof) at a purchase price of $1.50 per share (or pre-funded warrant in lieu thereof).

H.C. Wainwright & Co. acted as the exclusive placement agent for the offering.

The aggregate gross proceeds to the Company from the offering were approximately $6 million, before deducting the placement agent fees and other offering expenses payable by the Company. The Company currently intends to use the net proceeds from the offering toward working capital and general corporate purposes.

The securities described above were offered and sold by the Company pursuant to a “shelf” registration statement on Form S-3 (Registration No. 333-276814), including a base prospectus, previously filed with the Securities and Exchange Commission (SEC) on February 1, 2024 and declared effective by the SEC on February 12, 2024. The offering was made only by means of a prospectus supplement that forms a part of the registration statement. A prospectus supplement and an accompanying base prospectus relating to the offering were filed with the SEC and are available on the SEC’s website located at http://www.sec.gov. Electronic copies of the prospectus supplement and accompanying base prospectus may also be obtained by contacting H.C. Wainwright & Co., LLC at 430 Park Avenue, 3rd Floor, New York, NY 10022, by phone at (212) 856-5711 or e-mail at placements@hcwco.com.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy any of the securities described herein, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or jurisdiction.

About Annovis
Headquartered in Malvern, Pennsylvania, Annovis is dedicated to addressing neurodegeneration in diseases such as Alzheimer’s disease (AD) and Parkinson’s disease (PD). The Company is committed to developing innovative therapies that improve patient outcomes and quality of life. For more information, visit www.annovisbio.com and follow us on LinkedIn, YouTube, and X.

Forward-Looking Statements
This press release contains forward-looking statements under the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended, including, without limitation, statements regarding the use of proceeds from the offering. Actual results may differ due to various risks and uncertainties, including those outlined in the Company’s SEC filings under “Risk Factors” in its Annual Report on Form 10-K and Quarterly Reports on Form 10-Q. The Company undertakes no obligation to update forward-looking statements except as required by law.

Contact Information:
Annovis Bio Inc.
101 Lindenwood Drive
Suite 225
Malvern, PA 19355
www.annovisbio.com

Investor Contact:
Alexander Morin, Ph.D.
Director, Strategic Communications
Annovis Bio
ir@annovisbio.com

FAQ

What did Annovis (ANVS) announce on October 15, 2025 about a registered direct offering?

Annovis closed a registered direct offering of 4,000,000 shares (or pre-funded warrants) at $1.50 per share, raising approximately $6.0 million in gross proceeds.

How will Annovis (ANVS) use the proceeds from the October 15, 2025 offering?

The company intends to use net proceeds for working capital and general corporate purposes.

Who acted as placement agent for Annovis (ANVS) October 15, 2025 offering?

H.C. Wainwright & Co. served as the exclusive placement agent.

Where can investors find the prospectus for Annovis (ANVS) October 2025 offering?

The prospectus supplement and base prospectus are filed with the SEC and available at www.sec.gov under the company’s filings.

Were the Annovis (ANVS) offering proceeds reported net or gross on October 15, 2025?

The press release reports gross proceeds of approximately $6.0 million before placement agent fees and offering expenses.